Free Trial
NASDAQ:MGX

Metagenomi (MGX) Stock Price, News & Analysis

Metagenomi logo
$1.91 -0.14 (-6.83%)
Closing price 04:00 PM Eastern
Extended Trading
$1.95 +0.04 (+2.09%)
As of 05:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Metagenomi Stock (NASDAQ:MGX)

Key Stats

Today's Range
$1.90
$2.08
50-Day Range
$1.85
$3.79
52-Week Range
$1.61
$11.86
Volume
246,656 shs
Average Volume
1.05 million shs
Market Capitalization
$71.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.00
Consensus Rating
Moderate Buy

Company Overview

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Remove Ads

Metagenomi Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
36th Percentile Overall Score

MGX MarketRank™: 

Metagenomi scored higher than 36% of companies evaluated by MarketBeat, and ranked 734th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Metagenomi has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Metagenomi has received no research coverage in the past 90 days.

  • Read more about Metagenomi's stock forecast and price target.
  • Percentage of Shares Shorted

    12.11% of the float of Metagenomi has been sold short.
  • Short Interest Ratio / Days to Cover

    Metagenomi has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Metagenomi has recently increased by 3.11%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Metagenomi does not currently pay a dividend.

  • Dividend Growth

    Metagenomi does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.11% of the float of Metagenomi has been sold short.
  • Short Interest Ratio / Days to Cover

    Metagenomi has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Metagenomi has recently increased by 3.11%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Metagenomi has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Metagenomi this week, compared to 6 articles on an average week.
  • Search Interest

    Only 1 people have searched for MGX on MarketBeat in the last 30 days. This is a decrease of -96% compared to the previous 30 days.
  • MarketBeat Follows

    Only 5 people have added Metagenomi to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days.
Receive MGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Metagenomi and its competitors with MarketBeat's FREE daily newsletter.

MGX Stock News Headlines

DOGE Social Security bombshell?
Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social Security, finding what he says is widespread fraud across the agency.
Totus Medicines Appoints Simon Harnest As CFO
See More Headlines

MGX Stock Analysis - Frequently Asked Questions

Metagenomi's stock was trading at $3.61 on January 1st, 2025. Since then, MGX shares have decreased by 47.1% and is now trading at $1.91.
View the best growth stocks for 2025 here
.

Metagenomi (MGX) raised $94 million in an initial public offering (IPO) on Friday, February 9th 2024. The company issued 6,250,000 shares at a price of $15.00 per share.

Metagenomi's top institutional shareholders include Geode Capital Management LLC (1.57%), Norges Bank (0.96%), Peapod Lane Capital LLC (0.94%) and Pura Vida Investments LLC (0.71%). Insiders that own company stock include Holdings A/S Novo and Pamela Wapnick.
View institutional ownership trends
.

Shares of MGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Metagenomi investors own include Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD).

Company Calendar

Today
3/13/2025
Next Earnings (Estimated)
3/26/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MGX
Previous Symbol
NASDAQ:MGX
Fax
N/A
Employees
236
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.00
High Stock Price Target
$17.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+571.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-68,250,000.00
Net Margins
-134.27%
Pretax Margin
-137.13%

Debt

Sales & Book Value

Annual Sales
$55.08 million
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$72.42 million
Optionable
N/A
Beta
N/A
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?

Get This Free Report

This page (NASDAQ:MGX) was last updated on 3/13/2025 by MarketBeat.com Staff
From Our Partners